Your search returned 3 results.

Results
	1.	Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. MedStar authors: Aroda, Vanita R PMID: 29397376 Year: 2018 Citation: The Lancet Diabetes & Endocrinology. 6(4):275-286, 2018 04. Institution: MedStar Health Research Institute Medline publication type: Journal Article Form of publication: Journal Article All authors: Andreassen C, Aroda VR, Lingvay I, Ludemann J, Navarria A, Pratley RE, SUSTAIN 7 investigators, Viljoen A DOI: https://dx.doi.org/10.1016/S2213-8587(18)30024-X Add to cart (remove)
	2.	Effect of Dosage Reduction of Hypoglycemic Multidrug Regimens on the Incidences of Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramadan: A Randomized Controlled Trial. MedStar authors: Zaghlol, Raja PMID: 34305809 Year: 2021 Citation: Frontiers in Endocrinology. 12:613826, 2021. Institution: MedStar Washington Hospital Center Department: Internal Medicine Residency Medline publication type: Journal Article Form of publication: Journal Article All authors: Amarin JZ, Beirat AF, Hasan YY, Hassoun Al Najar AM, Qtaishat A, Tierney ME, Zaghlol LY, Zaghlol RY, Zayed AA DOI: https://dx.doi.org/10.3389/fendo.2021.613826 Add to cart (remove)
	3.	Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOW. MedStar authors: Ratner, Robert E PMID: 24705615 Year: 2014 Citation: Diabetes Care. 37(6):1706-11, 2014 Jun. Institution: MedStar Health Research Institute Medline publication type: Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Form of publication: Journal Article All authors: Banerji M, Bray GA, Buchanan TA, Clement SC, DeFronzo RA, Gastaldelli A, Henry RR, Kitabchi AE, Mudaliar S, Musi N, Ratner RE, Reaven PD, Schwenke DC, Stentz FB, Tripathy D DOI: http://dx.doi.org/10.2337/dc13-1745 Add to cart (remove)

Powered by Koha